Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as an Elite provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Bone Marrow Transplant. Dr. Forde is currently accepting new patients.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as a Distinguished provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Russell Hales, M.D., is an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also is director of the thoracic multidisciplinary clinic. His research focuses on reconstructing health delivery models to enhance value and improve clinical outcomes. He also studies the effect of immunotherapy and RT in thoracic tumors. Dr. Hales was awarded an R21 grant to study the use of dynamic MRI in predicting tumor motion in patient with lung cancer. Taken together, his research focuses on optimizing patient outcomes using resources from physics, engineering, biology and health delivery systems. Dr. Hales’ efforts extend beyond radiation oncology and clinical management. He has helped to lead in the thoracic oncology program, which includes 20 faculty members and nearly 50 staff, to help chart a vision for this program’s future. In the last four years, the program has gradually transitioned from The Johns Hopkins Hospital campus to Johns Hopkins Bayview Medical Center. Dr. Hales was tasked to head the building and design committee that worked with architects to create a structure conducive to 21st century oncology care. His work extends beyond the bricks and mortar of the new cancer center today to team development within the thoracic oncology program. Simply put, the thoracic oncology move was designed to conceptualize the transition of care from department-based to disease-based medicine. As such, Dr. Hales has worked to integrate the efforts of specialists in medical oncology, thoracic surgery, interventional pulmonology, pathology and radiology. These experts share a clinical space focused on thoracic malignancies and bring a patient-centered model of care to their group. Dr. Hales graduated from Brigham Young University Summa Cum Laude and Valedictorian in 2001. He attended Johns Hopkins Medicine and graduated with an M.D. in 2005. He trained on the Osler Medical Service and attended residency at Johns Hopkins. He joined the faculty at Hopkins in 2010. Dr. Hales focus in program building, research and clinical endeavors is robust, but he understands the key role of academia in training future leaders in medicine. He has been awarded Teacher of the Year in the department of radiation oncology at Hopkins for three of the last six years. He is a well-respected lecturer and travels nationally to speak at conferences and educational workshops about novel therapies in lung and esophagus cancer. Make A Gift. Dr. Hales is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy.

Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies. Dr. Anagnostou is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Gastroesophageal Junction Cancer.

Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3 year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breath of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. Dr. Yang is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Thymectomy.

Richard Battafarano, M.D., Ph.D., joins the Johns Hopkins Department of Surgery as director of the Division of General Thoracic Surgery and the first regional director of general thoracic surgery. He comes to Johns Hopkins from University of Maryland Medical System, where he was chief of the Division of Thoracic Surgery. Dr. Battafarano specializes in the treatment of benign and malignant diseases and lesions of the chest, including minimally invasive operations such as video-assisted thoracscopic surgery (VATS) for lung and esophageal cancers. He also has a special interest in treating Barretts esophagus, emphysema, mesothelioma and paraesophageal hernias. The focus of Dr. Battafaranos basic and translational research includes outcomes in the surgical management of early stage lung cancer patients with neuroendocrine histology, optimal management of lung cancer patients with mediastinal lymph node metastases, and the effect of survivin overexpression in the development of esophageal cancer. Dr. Battafarano sees patients at The Johns Hopkins Hospital and the Johns Hopkins Health Care & Surgery Centers at Green Spring Station and at White Marsh. Dr. Battafarano is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Lung Cancer, Thymic Epithelial Tumor, Pleuropulmonary Blastoma, Gastrectomy, and Endoscopy.

Azam Ghafoor is a Hospital Medicine provider in Bethesda, Maryland. Dr. Ghafoor is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Mesothelioma, Lung Cancer, and Small Cell Lung Cancer (SCLC).

Dr. Lam treats patients with lung cancer, esophageal cancer, mesothelioma, and other thoracic cancers. He directs the Thoracic Oncology Clinical Research Program and the Esophageal Cancer Research Program at Johns Hopkins. Dr. Lam is a clinical and translational researcher with a focus on cancer genomics, liquid biopsies, and novel immunotherapies such as vaccines and cell therapies. He has been recognized with a Conquer Cancer Foundation/ASCO Career Development Award, an LCFA/IASLC/BMS Young Investigator Award, and as a Gilead Research Scholar. Dr. Lam is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dr. Julianna Czum’s primary focus is cardiothoracic imaging, with clinical subspecialties in noninvasive cardiovascular and thoracic imaging. Dr. Czum earned her medical degree from UMDNJ - Robert Wood Johnson Medical School before going on to an internship at Mary Imogene Bassett Hospital and residency at St. Barnabas Medical Center. She completed a fellowship in cardiovascular magnetic resonance in a combined Henry Jackson Foundation-funded program at the National Institutes of Health, National Naval Medical Center and Uniformed Services University of the Health Sciences. Dr. Czum joined the diagnostic faculty in June 2022. Dr. Czum is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Pleurisy, ALK-Positive Non-Small Cell Lung Cancer, Chronic Cough, and Lung Nodules.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dr. Kristen Marrone is a thoracic medical oncology specialist in Baltimore, caring for patients with lung cancer and esophageal cancer. She is the Program Director of the Hematology/Medical Oncology Fellowship Program at the Johns Hopkins School of Medicine. Dr. Marrone received her undergraduate degree in psychology with a neuroscience concentration from Pennsylvania State University. She earned her M.D. from Drexel University College of Medicine. She completed her residency at Yale-New Haven Hospital and performed a fellowship in medical oncology at Johns Hopkins University School of Medicine. Dr. Marrone joined the Johns Hopkins faculty in 2017. Her research interests include clinical trial development and translational studies focusing on optimization of immunotherapy in oncogene driven non-small cell lung cancer. Dr. Marrone is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, the International Association for Study of Lung Cancer and the Society for Immunotherapy in Cancer. Dr. Marrone is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Gastroesophageal Junction Cancer.

Dr. K. Ranh Voong specializes in thoracic malignancies, including lung, esophageal, thymic cancers, and mesothelioma. She treats patients at both the Johns Hopkins Thoracic Center of Excellence at Johns Hopkins Bayview and at the Proton Center at Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, IMRT for tumors involving the chest. She is the Principal Investigator on grants from Lung Cancer Research Foundation and Hopkins-Wellspan. She is the Principal Investigator of a prospective study evaluating the immunogenic effects of SABR alone on systemic T cell response in patients with stage I NSCLC. She is the principal investigator of a multi-institutional prospective trial showing that routine review of patient-reported outcome measures informs radiation on-treatment toxicity burden assessment and care delivery. She was the Quality of Life Co-chair of a Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (NRG-LU006). She has been invited to participate in national and regularly lectures on thoracic malignancies and protons for thoracic malignancies therapy. In her research, Dr. Voong is dedicated to improving the outcomes of patients with thoracic malignancies, by exploring avenues to better understand and optimize the delivery of radiotherapy. Dr. Voong is also the Program Director for the Radiation Oncology Residency Program. She mentors residents, medical students. Make A Gift. Dr. Voong is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC).

Dr. Brian G. Johnson is the chief of interventional radiology at Sibley Memorial Hospital. Dr. Johnson practices out of Sibley Memorial Hospital in Washington, D.C., Suburban Hospital in Bethesda, MD and the Johns Hopkins Hospital in Baltimore, MD. Dr. Johnson graduated summa cum laude from University of Minnesota prior to earning his medical degree from Johns Hopkins University School of Medicine. He completed a residency in physical medicine and rehabilitation at Sinai Hospital of Baltimore, as well as a residency in diagnostic radiology at the University of Maryland Medical Center. Dr. Johnson also completed an interventional radiology fellowship at Johns Hopkins University. Dr. Johnson has been repeatedly named a Top Doctor by Washingtonian Magazine, as well as a Top MD by Consumers' Checkbook Magazine. He is a member of the American College of Radiology and the Society of Interventional Radiology. Videos Brian Johnson, M.D.Interventional Radiology Selected Publications Neuromodulatory effect of the atrial natriuretic factor clearance receptor binding peptide, cANF(4-23)-NH2 in the rabbit isolated vas deferentia, Johnson BG, Trachte GJ, Drewett JG, J Pharm & Exp Ther - 1/1/1991 Percutaneous Management of Renal and Renal-Pancreas Transplant Recipients Using CT Fluoroscopy: A Two Year Experience. Krebs TL, Johnson BG, Daly BD, Wong-You-Chong JJ, Bartlett ST, Radiological Society of North America Meeting, Chicago, IL - 1/29/1998 The hexagonal cell nitinol intravascular stent: a comparison of the effects of varying the stent wire gauge on the aorta and inferior vena cava in the swine animal model. Kuo J, Johnson BG, Venbrux AC, Olson JL, Samphilipo MA, Magee CA, Kobelja MA, Anderson JH, Osterman FA, American Roentgen Ray Society Annual Meeting, New Orleans, LA - 1/24/1994 The role of anticoagulation in the setting of a tethered vena cava filter in the swine animal model. Johnson BG, Reichle RL, Venbrux AC, Samphilipo MA, Magee CA, Anderson JH, Osterman FA, Society for Cardiovascular and Interventional Radiology Annual Meeting, Fort Lauderdale, FL - 1/1/1995. Dr. Johnson is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Bile Duct Obstruction, Vertebroplasty, and Bone Graft.

Dr. Elie Saad is an assistant professor in the nuclear medicine division. He received a master's degree in animal biology at the Lebanese University and went on to earn his medical degree at the Lebanese American University where he also completed his diagnostic and interventional radiology residency. He then completed fellowships in nuclear medicine and cross-sectional body imaging at the Johns Hopkins Hospital. Dr. Saad's main interests are in nuclear medicine and body imaging and their applications in cardiac diseases and oncology. Dr. Saad is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Lung Nodules, Metastatic Pleural Tumor, Neuroendocrine Tumor, and Mesothelioma.

Dr. James Facciola is a clinical instructor in the Johns Hopkins Medicine Department of Radiology and Radiological Sciences. He specializes in body magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and image-guided biopsy. Dr. Facciola graduated from the Temple University School of Medicine in 2013. He subsequently completed a preliminary surgical internship at Temple University Hospital in Philadelphia, PA followed by a diagnostic radiology residency at Temple University Hospital. Following residency, he completed a year-long fellowship in cross-sectional imaging at Johns Hopkins. Dr. Facciola’s research has included study of the anatomic changes seen in the male and female pelvis in children with bladder exstrophy. He joins the Johns Hopkins faculty in July 2019. Dr. Facciola is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Pleurisy, Exstrophy of the Bladder, Pleural Effusion, and Pancreatic Cancer.

Selamawit Addissie, M.D., received her medical degree from The Ohio State University College of Medicine. She completed her residency in Internal Medicine from Johns Hopkins Bayview Medical Center. During medical school, Dr. Addissie volunteered and worked with diverse groups of patients and formed meaningful interactions, which helped broaden her cultural competency. Dr. Addissie is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. Her top area of expertise is Mesothelioma.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.

Petr Hausner is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Hausner is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Familial Colorectal Cancer, and Anal Cancer. Dr. Hausner is currently accepting new patients.